A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)
Clinical Trial Grant
Administered By
Surgery
Awarded By
Biogen MA, Inc.
Start Date
March 31, 2025
End Date
March 31, 2030
Administered By
Surgery
Awarded By
Biogen MA, Inc.
Start Date
March 31, 2025
End Date
March 31, 2030